Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update
Aadi Bioscience (NASDAQ: AADI), a commercial-stage precision oncology company, has announced it will host a conference call and live webcast on August 7, 2024, at 8:30 am EDT to report its second quarter 2024 financial results and provide recent corporate updates. The company focuses on developing and commercializing therapies for cancers with alterations in the mTOR pathway.
Participants can access the webcast on the 'Investors & News' page of Aadi Bioscience's website. For telephone participation, registration is required in advance. Upon registration, participants will receive a confirmation email with dial-in details and unique access codes. A replay of the conference call and webcast will be available on the company's website for at least 30 days after the event.
Aadi Bioscience (NASDAQ: AADI), un'azienda di oncologia di precisione in fase commerciale, ha annunciato che ospiterà una teleconferenza e una diretta web il 7 agosto 2024, alle 8:30 EDT per riportare i suoi risultati finanziari del secondo trimestre 2024 e fornire aggiornamenti aziendali recenti. L'azienda si concentra sullo sviluppo e la commercializzazione di terapie per i tumori con alterazioni nel percorso mTOR.
I partecipanti possono accedere alla diretta web nella pagina 'Investitori & Notizie' del sito di Aadi Bioscience. Per la partecipazione telefonica, è necessaria la registrazione anticipata. Una volta registrati, i partecipanti riceveranno un'email di conferma con i dettagli per la chiamata e codici di accesso unici. Una registrazione della teleconferenza e della diretta sarà disponibile sul sito dell'azienda per almeno 30 giorni dopo l'evento.
Aadi Bioscience (NASDAQ: AADI), una empresa de oncología de precisión en fase comercial, ha anunciado que llevará a cabo una conferencia telefónica y una transmisión web en vivo el 7 de agosto de 2024, a las 8:30 a.m. EDT para informar sobre sus resultados financieros del segundo trimestre de 2024 y proporcionar actualizaciones recientes de la empresa. La compañía se centra en desarrollar y comercializar terapias para cánceres con alteraciones en la vía mTOR.
Los participantes pueden acceder a la transmisión web en la página 'Inversores y Noticias' del sitio web de Aadi Bioscience. Para la participación telefónica, se requiere registro por adelantado. Una vez registrados, los participantes recibirán un correo electrónico de confirmación con los detalles de acceso y códigos únicos. Una repetición de la conferencia telefónica y la transmisión estará disponible en el sitio web de la empresa durante al menos 30 días después del evento.
Aadi Bioscience (NASDAQ: AADI)는 상업 단계의 정밀 온콜로지 기업으로, 2024년 8월 7일 오전 8시 30분 EDT에 분기별 실적 발표 및 최근 기업 업데이트를 포함한 회의 전화를 진행하고 생중계할 것이라고 발표했습니다. 이 회사는 mTOR 경로에 변화를 가진 암 치료제를 개발하고 상업화하는 데 중점을 두고 있습니다.
참가자들은 Aadi Bioscience의 웹사이트 '투자자 및 뉴스' 페이지에서 생중계에 접근할 수 있습니다. 전화 참여를 원할 경우 사전 등록이 요구됩니다. 등록 후 참가자들은 다이얼 인 세부사항과 고유 접근 코드가 포함된 확인 이메일을 받게 됩니다. 회의 전화와 웹 캐스트의 재생은 이벤트 후 최소 30일 동안 회사 웹사이트에서 제공됩니다.
Aadi Bioscience (NASDAQ: AADI), une entreprise d'oncologie de précision en phase commerciale, a annoncé qu'elle animera une conférence téléphonique et un webinaire en direct le 7 août 2024 à 8h30 EDT pour présenter ses résultats financiers du deuxième trimestre 2024 et fournir des mises à jour récentes sur l'entreprise. L'entreprise se concentre sur le développement et la commercialisation de thérapies pour les cancers présentant des modifications dans la voie mTOR.
Les participants peuvent accéder au webinaire sur la page 'Investisseurs & Actualités' du site web d’Aadi Bioscience. Pour une participation téléphonique, une inscription préalable est requise. Une fois inscrits, les participants recevront un courriel de confirmation contenant les détails de connexion et des codes d'accès uniques. Un enregistrement de la conférence téléphonique et du webinaire sera disponible sur le site de l'entreprise pendant au moins 30 jours après l'événement.
Aadi Bioscience (NASDAQ: AADI), ein Unternehmen für präzise Onkologie in der kommerziellen Phase, hat angekündigt, dass es am 7. August 2024 um 8:30 Uhr EDT eine Telefonkonferenz und einen Live-Webcast abhalten wird, um über seine finanziellen Ergebnisse des zweiten Quartals 2024 zu berichten und aktuelle Unternehmensneuigkeiten zu teilen. Das Unternehmen konzentriert sich auf die Entwicklung und Kommerzialisierung von Therapien für Krebserkrankungen mit Veränderungen im mTOR-Signalweg.
Teilnehmer können den Webcast auf der Seite 'Investoren & Nachrichten' der Website von Aadi Bioscience abrufen. Für die telefonische Teilnahme ist eine vorherige Registrierung erforderlich. Nach der Anmeldung erhalten die Teilnehmer eine Bestätigungs-E-Mail mit den Einwahldaten und einzigartigen Zugangscodes. Eine Wiederholung der Telefonkonferenz und des Webcasts wird auf der Website des Unternehmens für mindestens 30 Tage nach der Veranstaltung verfügbar sein.
- Aadi Bioscience is a commercial-stage company, indicating it has products on the market
- The company is focused on precision oncology, a growing field in cancer treatment
- Aadi is providing transparency by hosting a public conference call for investors and analysts
- None.
Company to Host Conference Call and Webcast on August 7, 2024
Conference Call Information
Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. To participate via telephone, please register in advance here: Conference Registration (vevent.com). Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the website for at least 30 days.
About Aadi Bioscience, Inc.
Aadi is a commercial-stage precision oncology company focused on the development and commercialization of therapies for cancers with alterations in the mTOR pathway, a key regulator of cell growth and cancer progression. To unlock the full potential of mTOR inhibition, Aadi uniquely combines nanoparticle albumin-bound (nab) technology with the potent mTOR inhibitor, sirolimus. Aadi received FDA approval and commercializes FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Aadi is exploring nab-sirolimus in PRECISION1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. Aadi is also exploring nab-sirolimus in two single-indication Phase 2 trials for difficult-to-treat mTOR-driven cancers: neuroendocrine tumors (NETs) of the lung, gastrointestinal tract and pancreas, and advanced or recurrent endometrioid-type endometrial cancer (EEC) in combination with letrozole. More information on Aadi's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.
Contact:
IR@aadibio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-report-second-quarter-2024-results-and-corporate-update-302211486.html
SOURCE Aadi Bioscience
FAQ
When will Aadi Bioscience (AADI) report its Q2 2024 financial results?
How can investors access Aadi Bioscience's (AADI) Q2 2024 earnings call?
What is the focus of Aadi Bioscience's (AADI) drug development?
Will there be a replay available for Aadi Bioscience's (AADI) Q2 2024 earnings call?
